Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

Completed · Not applicable

Conditions studied: Sarcoma, Kaposi, HIV Infections

In brief

The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.

Key facts

Study ID

NCT00002226

Run by

SUGEN

People needed

30

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• You may be eligible for this study if you:
• Are at least 18 years old.
• Are HIV-positive.
• Have KS with at least 5 skin lesions.
• Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy.
• Agree to use effective methods of birth control during the study.

You may not qualify if…

• You will not be eligible for this study if you:
• Have had surgery within 4 weeks of study entry.
• Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry.
• Have pulmonary KS (KS in your lungs).
• Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers.
• Are allergic to Cremophor.
• Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy).
• Are pregnant.

Where it is running

• Norris Cancer Ctr / USC — Los Angeles, California, United States
• UCLA Care Ctr / Ctr for Hlth Sciences — Los Angeles, California, United States
• Saint Francis Mem Hosp / HIV Care Unit — San Francisco, California, United States
• New York Univ Med Ctr — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.